EP3197911A4 - Verbesserter therapeutische kontrolle von heterodimeren und einkettigen formen von interleukin-12 - Google Patents

Verbesserter therapeutische kontrolle von heterodimeren und einkettigen formen von interleukin-12 Download PDF

Info

Publication number
EP3197911A4
EP3197911A4 EP15844248.3A EP15844248A EP3197911A4 EP 3197911 A4 EP3197911 A4 EP 3197911A4 EP 15844248 A EP15844248 A EP 15844248A EP 3197911 A4 EP3197911 A4 EP 3197911A4
Authority
EP
European Patent Office
Prior art keywords
heterodimeric
interleukin
single chain
improved therapeutic
chain forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15844248.3A
Other languages
English (en)
French (fr)
Other versions
EP3197911A1 (de
Inventor
Charles C. Reed
Gregory Ian Frost
Joan Mazzarelli SOPCZYNSKI
Chi Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Precigen Inc
Original Assignee
Intrexon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrexon Corp filed Critical Intrexon Corp
Publication of EP3197911A1 publication Critical patent/EP3197911A1/de
Publication of EP3197911A4 publication Critical patent/EP3197911A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP15844248.3A 2014-09-22 2015-09-21 Verbesserter therapeutische kontrolle von heterodimeren und einkettigen formen von interleukin-12 Withdrawn EP3197911A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462053628P 2014-09-22 2014-09-22
US201462074875P 2014-11-04 2014-11-04
PCT/US2015/051246 WO2016048903A1 (en) 2014-09-22 2015-09-21 Improved therapeutic control of heterodimeric and single chain forms of interleukin-12

Publications (2)

Publication Number Publication Date
EP3197911A1 EP3197911A1 (de) 2017-08-02
EP3197911A4 true EP3197911A4 (de) 2018-06-20

Family

ID=55581867

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15844248.3A Withdrawn EP3197911A4 (de) 2014-09-22 2015-09-21 Verbesserter therapeutische kontrolle von heterodimeren und einkettigen formen von interleukin-12

Country Status (7)

Country Link
US (1) US20170291934A1 (de)
EP (1) EP3197911A4 (de)
AU (1) AU2015321603A1 (de)
CA (1) CA2962099A1 (de)
IL (1) IL251326A0 (de)
SG (1) SG11201702295UA (de)
WO (1) WO2016048903A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2251034T3 (pl) 2005-12-02 2018-07-31 Icahn School Of Medicine At Mount Sinai Chimeryczne wirusy prezentujące nienatywne białka powierzchniowe i zastosowania tych wirusów
CA2905272A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
CN107073099B (zh) 2014-02-27 2022-09-27 默沙东公司 用于治疗癌症的联合方法
RU2749113C2 (ru) 2015-04-22 2021-06-04 Куревак Аг Содержащая рнк композиция для лечения опухолевых заболеваний
CN106520778A (zh) * 2015-09-09 2017-03-22 北京锤特生物科技有限公司 改造的白介素12及其在制备治疗肿瘤的药物中的用途
AU2016334401A1 (en) 2015-10-10 2018-04-26 Intrexon Corporation Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
EA201890861A1 (ru) 2015-11-09 2018-10-31 Иммьюн Дизайн Корп. Композиции, содержащие лентивирусные векторы, экспрессирующие il-12, и способы их применения
JP7246930B2 (ja) 2016-05-18 2023-03-28 モデルナティエックス インコーポレイテッド インターロイキン－１２（ｉｌ１２）をコードするポリヌクレオチドおよびその使用
US11421010B2 (en) 2016-10-07 2022-08-23 Board Of Regents, The University Of Texas System T cells expressing membrane-anchored IL-12 for the treatment of cancer
CN108147990B (zh) * 2016-12-02 2023-01-24 上海中医药大学 一种膜锚定元件及其应用
EP3568474A1 (de) 2017-01-10 2019-11-20 Intrexon Corporation Modulation der expression von polypeptiden über neue genschalterexpressionssysteme
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
JP2020517615A (ja) * 2017-04-21 2020-06-18 プレシゲン，インコーポレイテッド 硬皮症の処置のための、マトリックス金属タンパク質分解酵素を含む自己由来細胞の送達
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
AU2018270111B2 (en) * 2017-05-18 2022-07-14 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
IL306102B1 (en) 2017-06-07 2024-09-01 Precigen Inc Expression of new cell markers
EP3638289A4 (de) 2017-06-12 2021-03-24 Obsidian Therapeutics, Inc. Pde5-zusammensetzungen und verfahren zur immuntherapie
EP3675892A4 (de) 2017-07-03 2021-10-06 Torque Therapeutics, Inc. Immunstimulatorische fusionsmoleküle und verwendungen davon
SG11202008508QA (en) 2018-03-06 2020-10-29 Precigen Inc Hepatitis b vaccines and uses of the same
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
EP3849589A1 (de) * 2018-09-14 2021-07-21 ModernaTX, Inc. Verfahren und zusammensetzungen zur krebsbehandlung mit mrna-therapeutika
MA53822A (fr) 2018-10-03 2021-08-11 Xencor Inc Protéines de fusion fc hétérodimères d'il -12
WO2020086742A1 (en) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Er tunable protein regulation
WO2020123716A1 (en) 2018-12-11 2020-06-18 Obsidian Therapeutics, Inc. Membrane bound il12 compositions and methods for tunable regulation
WO2020160350A1 (en) * 2019-02-01 2020-08-06 Board Of Regents, The University Of Texas System Modified il-12 t cell therapy for the treatment of cancer
EP3983537A1 (de) 2019-06-12 2022-04-20 Obsidian Therapeutics, Inc. Ca2-zusammensetzungen und verfahren zur abstimmbaren regulierung
US20230092895A1 (en) 2019-08-30 2023-03-23 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
US11851466B2 (en) 2019-10-03 2023-12-26 Xencor, Inc. Targeted IL-12 heterodimeric Fc-fusion proteins
EP4061417A4 (de) * 2019-11-20 2023-10-11 University of Pittsburgh - of the Commonwealth System of Higher Education Vaccinia-viren und verfahren zur verwendung von vaccinia-viren
US20230399370A1 (en) * 2019-11-22 2023-12-14 Alaunos Therapeutics, Inc. Methods of treating glioblastoma
MX2022012823A (es) * 2020-04-17 2023-01-04 Univ Leland Stanford Junior Polipéptidos modificados de il-12 e il-23 y usos de los mismos.
EP4143323A1 (de) * 2020-04-30 2023-03-08 VLP Therapeutics, Inc. Cytokinimmuntherapie
CA3215830A1 (en) 2021-04-19 2022-10-27 Rafael CUBAS Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
AU2022369312A1 (en) 2021-10-20 2024-05-02 Synthekine, Inc. Heterodimeric fc cytokines and uses thereof
WO2024030758A1 (en) 2022-08-01 2024-02-08 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2024149373A1 (en) * 2023-01-12 2024-07-18 Chengdu Ucello Biotechnology Co., Limited Membrane-anchored cytokines, engineered immune cells, and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999060135A1 (en) * 1998-05-21 1999-11-25 Cancer Research Ventures Limited Generation of multiple gene products from chimeric fusion proteins by cleavage with ubiquitous endoproteases
WO2015095249A1 (en) * 2013-12-18 2015-06-25 Intrexon Corporation Single chain il-12 nucleic acids, polypeptids, and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0956301A2 (de) * 1996-10-18 1999-11-17 Valentis Inc. Il-12 genexpressions- und transfersysteme und verwendungen
CA2402213C (en) * 2000-03-15 2012-08-07 Pohang University Of Science And Technology Genes of il-12p40 subunit mutated for improving the activity of il-12 and use thereof for dna vaccine adjuvant
EP1418184A1 (de) * 2002-11-08 2004-05-12 Cell Center Cologne GmbH Aus den p40 und p35 Untereinheiten des IL-12 und ein ScFv bestehendes rekombinantes Protein und seine Verwendung
JP2009500021A (ja) * 2005-06-30 2009-01-08 アーケミックス コーポレイション サイトカインのｉｌ−１２ファミリーのポリヌクレオチドおよびポリペプチド

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999060135A1 (en) * 1998-05-21 1999-11-25 Cancer Research Ventures Limited Generation of multiple gene products from chimeric fusion proteins by cleavage with ubiquitous endoproteases
WO2015095249A1 (en) * 2013-12-18 2015-06-25 Intrexon Corporation Single chain il-12 nucleic acids, polypeptids, and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LODE H N ET AL: "GENE THERAPY WITH A SINGLE CHAIN INTERLEUKIN 12 FUSION PROTEIN INDUCES T CELL-DEPENDENT PROTECTIVE IMMUNITY IN A SYNGENEIC MODEL OF MURINE NEUROBLASTOMA", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, NATIONAL ACADEMY OF SCIENCES, US, vol. 95, 1 March 1998 (1998-03-01), pages 2475 - 2480, XP002943730, ISSN: 0027-8424, DOI: 10.1073/PNAS.95.5.2475 *
See also references of WO2016048903A1 *
WEN-YU PAN ET AL: "Cancer Immunotherapy Using a Membrane-bound Interleukin-12 With B7-1 Transmembrane and Cytoplasmic Domains", MOLECULAR THERAPY, vol. 20, no. 5, 1 May 2012 (2012-05-01), US, pages 927 - 937, XP055327744, ISSN: 1525-0016, DOI: 10.1038/mt.2012.10 *

Also Published As

Publication number Publication date
CA2962099A1 (en) 2016-03-31
EP3197911A1 (de) 2017-08-02
US20170291934A1 (en) 2017-10-12
SG11201702295UA (en) 2017-04-27
WO2016048903A1 (en) 2016-03-31
AU2015321603A1 (en) 2017-04-13
IL251326A0 (en) 2017-05-29

Similar Documents

Publication Publication Date Title
IL251326A0 (en) Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
HUS2400014I1 (hu) Terápiás ellenanyagok és alkalmazásaik
IL258931A (en) Medicinal compounds and methods
EP3377102A4 (de) Anti-pd-1-antikörper und deren therapeutische verwendungen
IL248211A0 (en) mdm2 inhibitors and therapeutic methods using them
EP3245232A4 (de) Heterodimeres cas9 und verfahren zur verwendung davon
EP3204360A4 (de) Therapeutische verbindungen und verwendungen davon
EP3137606A4 (de) Verfahren und modifikationen zur herstellung von ssrnai-verbindungen mit erhöhter aktivität, wirksamkeit und wirkungsdauer
GB201404470D0 (en) Therapeutic methods and materials
HK1247091A1 (zh) 治療抗體及其用途
EP3265476A4 (de) Protoxin-vii-varianten und verfahren zur verwendung
IL247325A0 (en) Therapeutic methods using noribogaine and related compounds
EP3367913A4 (de) Therapeutisches verfahren und vorrichtung
EP3113771A4 (de) Therapeutische verwendung von ibogain und verwandten verbindungen
IL270011B (en) Medicinal compounds and methods
EP3277304A4 (de) Protoxin-vii-varianten und verfahren zur verwendung
EP3353159A4 (de) Modifizierte zytotoxine und ihre therapeutische verwendung
EP3267796A4 (de) Insektizide kombinationen von pip-72 und verfahren zur verwendung
EP3204003A4 (de) Selenzucker und therapeutische verwendungen davon
AU2017901457A0 (en) Therapeutic compounds and methods
AU2017901380A0 (en) Therapeutic uses and methods
AU2015901423A0 (en) Therapeutic antibodies and uses thereof
AU2016901176A0 (en) Personal Therapeutic Device
AU2015901219A0 (en) Therapeutic compounds and uses thereof
AU2014901186A0 (en) Therapeutic Agents and Uses Thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20170420

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/567 20060101ALI20180207BHEP

Ipc: C07K 14/54 20060101AFI20180207BHEP

Ipc: C12P 21/02 20060101ALI20180207BHEP

Ipc: A61K 45/00 20060101ALI20180207BHEP

Ipc: G01N 33/50 20060101ALI20180207BHEP

Ipc: A61K 38/00 20060101ALI20180207BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20180523

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/50 20060101ALI20180516BHEP

Ipc: A61K 38/00 20060101ALI20180516BHEP

Ipc: C07K 14/54 20060101AFI20180516BHEP

Ipc: C12P 21/02 20060101ALI20180516BHEP

Ipc: G01N 33/567 20060101ALI20180516BHEP

Ipc: A61K 45/00 20060101ALI20180516BHEP

17Q First examination report despatched

Effective date: 20190514

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20191121